Cargando…

The First Case of Co-Infection with Omicron Subvariants BA.5.2.48 and BF.7.14 — Chongqing Municipality, China, February 2023

Detalles Bibliográficos
Autores principales:	Su, Kun, Huang, Ying, Chen, Xiaofeng, Liu, Fangyuan, Yan, Qi, Jiang, Xinyu, Xu, Jing, Hao, Yongdong, Yan, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023
Materias:	Notes from the Field
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061799/ https://www.ncbi.nlm.nih.gov/pubmed/37009171 http://dx.doi.org/10.46234/ccdcw2023.046

Ejemplares similares

Genomic Recombination of SARS-CoV-2 Subvariants BA.5.2.48 and BF.7.14 — China, 2023
por: Zhang, Zhongxian, et al.
Publicado: (2023)

A Comparison of Clinical Characteristics of Infections with SARS-CoV-2 Omicron Subvariants BF.7.14 and BA.5.2.48 — China, October–December 2022
por: Huo, Da, et al.
Publicado: (2023)

An Outbreak of SARS-CoV-2 Omicron Subvariant BA.2.76 in an Outdoor Park — Chongqing Municipality, China, August 2022
por: Qi, Li, et al.
Publicado: (2022)

BF.7 Omicron subvariant in India and China: a raising concern – correspondence
por: Sah, Ranjit, et al.
Publicado: (2023)

Possible threat of the Omicron subvariant BF.7 to FIH Hockey World Cup 2023 in particular and the South-East Asia Region in general
por: Mohapatra, Ranjan K., et al.
Publicado: (2023)

The First Outbreak of Omicron Subvariant BA.5.2 — Beijing Municipality, China, July 4, 2022
por: Feng, Zhaomin, et al.
Publicado: (2022)

Detection of the Omicron BA.2.75 subvariant in Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Modelling the impact of the Omicron BA.5 subvariant in New Zealand
por: Lustig, Audrey, et al.
Publicado: (2023)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Omicron subvariant BA.5 efficiently infects lung cells
por: Hoffmann, Markus, et al.
Publicado: (2023)

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2023)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
por: Ghosh, Shankhaneel, et al.
Publicado: (2023)

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)
por: Wang, Hongyu, et al.
Publicado: (2023)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

First Imported Case of SARS-CoV-2 Omicron Subvariant BA.5 — Shanghai Municipality, China, May 13, 2022
por: Jiang, Hui, et al.
Publicado: (2022)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Epidemiological and clinical features of children with the Omicron BA.5.2 subvariant in Guangzhou
por: Li, Feng, et al.
Publicado: (2023)

Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa
por: Jassat, Waasila, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

BF.7 Omicron subvariant (BA.5.2.1.7) posing fears of a rise in COVID-19 cases again: a critical appraisal and salient counteracting strategies
por: Dhama, Kuldeep, et al.
Publicado: (2023)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
por: Wang, Qian, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
por: Xu, Cong, et al.
Publicado: (2023)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
por: Faraone, Julia N., et al.
Publicado: (2023)

Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China
por: Sun, Yamin, et al.
Publicado: (2023)

Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
por: Lyngse, Frederik Plesner, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i75j3ob5e8ul7sq1l064cg4oeg